Bristol’s Opdivo Delay May Help It Beat Out BRAF Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm announces three-month user fee extension for first-line melanoma claim for Opdivo, but the firm’s statement suggests a silver lining.